title: Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance.
abstract: Extensive scientific efforts are directed towards finding new and improved platinum anticancer agents. A promising approach is the encapsulation of cisplatin in sterically stabilized, long circulating, PEGylated 100 nm liposomes. This liposomal cisplatin (STEALTH cisplatin, formerly known as SPI-77) shows excellent stability in plasma and has a longer circulation time, greater efficacy and lower toxicity than much free cisplatin. However, so far, the physicochemical characterization of STEALTH cisplatin has been limited to size distribution, drug-to-lipid ratio and stability. Information on the physical state of the drug in the liposome aqueous phases and the drug's interaction with the liposome membrane has been lacking. This study was aimed at filling this gap. We report a multinuclear NMR study in which several techniques have been used to assess the physical nature of cisplatin in liposomal formulations and if and to what extent the drug affects the liposome phospholipids. Since NMR detects only the soluble cisplatin in the liposomes and not the insoluble drug, combining NMR and atomic absorption data enables one to determine how much of the encapsulated drug is soluble in the intraliposomal aqueous phase. Our results indicate that almost all of the cisplatin remains intact during the loading process, and that the entire liposomal drug is present in a soluble form in the internal aqueous phase of the liposomes.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, University of Jerusalem, Israel.
authors.forename: T
authors.initials: T
authors.lastname: Peleg-Shulman
authors.forename: D
authors.initials: D
authors.lastname: Gibson
authors.forename: R
authors.initials: R
authors.lastname: Cohen
authors.forename: R
authors.initials: R
authors.lastname: Abra
authors.forename: Y
authors.initials: Y
authors.lastname: Barenholz
mesh_terms: D002021:Buffers; D002945:Cisplatin / Q000737:chemistry*; D004337:Drug Carriers; D004355:Drug Stability; D006639:Histidine / Q000031:analogs & derivatives; D007554:Isotopes; D008081:Liposomes / Q000737:chemistry*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D009587:Nitrogen Isotopes; D010743:Phospholipids / Q000737:chemistry; D010759:Phosphorus Isotopes; D010984:Platinum; D011092:Polyethylene Glycols; D012995:Solubility; D013054:Spectrophotometry, Atomic
chemical_list: D002021:Buffers; D004337:Drug Carriers; D007554:Isotopes; D008081:Liposomes; D009587:Nitrogen Isotopes; D010743:Phospholipids; D010759:Phosphorus Isotopes; D011092:Polyethylene Glycols; D010984:Platinum; D006639:Histidine; C023495:N-acetylhistidine; D002945:Cisplatin